SDK2: A Drug Target / Disease Biomarker (G54549)

Target Name: SDK2

NCBI ID: G54549

SDK2

SDK2: A Drug Target / Disease Biomarker

SDK2 (Src-Tyrosine Kinase 2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the SDK family of proteins, which are known for their role in cell signaling. SDK2 has been shown to play a role in the regulation of cellular processes such as cell growth, differentiation, and survival.

One of the unique features of SDK2 is its structure. It consists of a single polypeptide chain that is composed of 214 amino acid residues. The protein has a calculated molecular mass of 21.1 kDa. SDK2 is expressed in various tissues and has been shown to be involved in a number of cellular processes.

One of the key functions of SDK2 is its role in cell signaling. It is a potent tyrosine kinase, which means that it can bind to and activate tyrosine kinases. Tyrosine kinases are a family of proteins that are involved in the regulation of cellular processes such as cell growth, differentiation, and survival. Activation of SDK2 by tyrosine kinases can lead to the downstream regulation of various cellular processes.

In addition to its role in cell signaling, SDK2 is also involved in the regulation of cellular processes such as cell adhesion and migration. It has been shown to play a role in the regulation of tight junction formation, which is the process by which cells stick together and form tissues. SDK2 has also been shown to be involved in the regulation of cell migration, which is the process by which cells move from one location to another in the body.

The structure and function of SDK2 have led it to be considered as a drug target. SDK2 has been shown to be involved in the regulation of a number of cellular processes, making it an attractive target for drug development. For example, inhibition of SDK2 has been shown to have therapeutic effects in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In addition to its potential as a drug target, SDK2 has also been shown to be a potential biomarker. Its expression has been shown to be regulated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. By studying the expression and function of SDK2, researchers may be able to develop new diagnostic tests and therapeutic strategies for these diseases.

In conclusion, SDK2 is a protein that is expressed in various tissues throughout the body and is involved in a number of cellular processes. Its structure and function as a tyrosine kinase make it an attractive target for drug development. Additionally, its role in cell signaling and regulation of cellular processes makes it a potential biomarker for a number of diseases. Further research is needed to fully understand the role of SDK2 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Sidekick Cell Adhesion Molecule 2

Functions: Adhesion molecule that promotes lamina-specific synaptic connections in the retina and is specifically required for the formation of neuronal circuits that detect motion. Acts by promoting formation of synapses between two specific retinal cell types: the retinal ganglion cells W3B-RGCs and the excitatory amacrine cells VG3-ACs. Formation of synapses between these two cells plays a key role in detection of motion. Promotes synaptic connectivity via homophilic interactions

The "SDK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets